CA3163321C - Methods for dose initiation of aripiprazole treatments - Google Patents

Methods for dose initiation of aripiprazole treatments Download PDF

Info

Publication number
CA3163321C
CA3163321C CA3163321A CA3163321A CA3163321C CA 3163321 C CA3163321 C CA 3163321C CA 3163321 A CA3163321 A CA 3163321A CA 3163321 A CA3163321 A CA 3163321A CA 3163321 C CA3163321 C CA 3163321C
Authority
CA
Canada
Prior art keywords
aripiprazole
oral
patient
day
injection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3163321A
Other languages
English (en)
French (fr)
Other versions
CA3163321A1 (en
Inventor
Matthew HARLIN
Xiaofeng Wang
Yanlin Wang
Arash Raoufinia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=75581573&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3163321(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Priority to CA3212191A priority Critical patent/CA3212191A1/en
Publication of CA3163321A1 publication Critical patent/CA3163321A1/en
Application granted granted Critical
Publication of CA3163321C publication Critical patent/CA3163321C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hospice & Palliative Care (AREA)
CA3163321A 2020-04-01 2021-04-01 Methods for dose initiation of aripiprazole treatments Active CA3163321C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3212191A CA3212191A1 (en) 2020-04-01 2021-04-01 Methods for dose initiation of aripiprazole treatments

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063003544P 2020-04-01 2020-04-01
US63/003,544 2020-04-01
PCT/JP2021/014194 WO2021201239A1 (en) 2020-04-01 2021-04-01 Methods for dose initiation of aripiprazole treatments

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3212191A Division CA3212191A1 (en) 2020-04-01 2021-04-01 Methods for dose initiation of aripiprazole treatments

Publications (2)

Publication Number Publication Date
CA3163321A1 CA3163321A1 (en) 2021-10-07
CA3163321C true CA3163321C (en) 2023-12-19

Family

ID=75581573

Family Applications (3)

Application Number Title Priority Date Filing Date
CA3163321A Active CA3163321C (en) 2020-04-01 2021-04-01 Methods for dose initiation of aripiprazole treatments
CA3212191A Pending CA3212191A1 (en) 2020-04-01 2021-04-01 Methods for dose initiation of aripiprazole treatments
CA3136727A Pending CA3136727A1 (en) 2020-04-01 2021-04-01 Methods of administering an arip-iprazole injectable preparation

Family Applications After (2)

Application Number Title Priority Date Filing Date
CA3212191A Pending CA3212191A1 (en) 2020-04-01 2021-04-01 Methods for dose initiation of aripiprazole treatments
CA3136727A Pending CA3136727A1 (en) 2020-04-01 2021-04-01 Methods of administering an arip-iprazole injectable preparation

Country Status (16)

Country Link
US (6) US20230129919A1 (https=)
EP (3) EP4467194A3 (https=)
JP (4) JP7733000B2 (https=)
KR (3) KR20220161402A (https=)
CN (3) CN115379842A (https=)
AU (2) AU2021248212A1 (https=)
BR (2) BR112022018721A2 (https=)
CA (3) CA3163321C (https=)
ES (1) ES2995466T3 (https=)
HR (1) HRP20241574T1 (https=)
HU (1) HUE069157T2 (https=)
MX (2) MX2022012354A (https=)
PL (1) PL4125903T3 (https=)
TW (3) TW202523329A (https=)
WO (2) WO2021201238A1 (https=)
ZA (1) ZA202210633B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050032811A1 (en) * 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
HUE069157T2 (hu) 2020-04-01 2025-02-28 Otsuka Pharma Co Ltd Eljárások aripiprazol kezelések adagoláskezdésére
CA3197997A1 (en) 2023-03-17 2025-01-23 Otsuka Pharmaceutical Co., Ltd. METHODS FOR DISPERSING INJECTABLE PREPARATIONS OF ARIPIPRAZOLE
CN120957722A (zh) 2023-04-26 2025-11-14 大塚制药株式会社 用阿立哌唑治疗精神分裂症或i型双相障碍的剂量启动

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US20050032811A1 (en) 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
UA82561C2 (uk) 2003-10-23 2008-04-25 Оцука Фармасьютикалз Ко., Лтд. Стерильна ін'єкційна композиція арипіпразолу з контрольованим вивільненням, спосіб її виготовлення та спосіб лікування шизофренії
UA96342C2 (en) 2007-06-25 2011-10-25 Оцука Фармасьютикал Ко., Лтд. Microspheres having core/shell structure
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
US10525057B2 (en) * 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
EP4082546A1 (en) 2017-05-16 2022-11-02 Bow River LLC Methods of treatment with cyp3a4 substrate drugs
EP3761983A1 (en) * 2018-03-05 2021-01-13 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN108498456B (zh) 2018-05-16 2021-01-01 丽珠医药集团股份有限公司 一种阿立哌唑缓释微球及其制备方法
CN110327296B (zh) 2019-08-06 2021-10-22 深圳市泛谷药业股份有限公司 一种阿立哌唑长效注射制剂及其制备方法
HUE069157T2 (hu) 2020-04-01 2025-02-28 Otsuka Pharma Co Ltd Eljárások aripiprazol kezelések adagoláskezdésére

Also Published As

Publication number Publication date
JP2025020306A (ja) 2025-02-12
EP3941470A1 (en) 2022-01-26
KR20240165486A (ko) 2024-11-22
TW202523329A (zh) 2025-06-16
JP7733000B2 (ja) 2025-09-02
EP4467194A3 (en) 2025-01-08
JP7584535B2 (ja) 2024-11-15
US20220160621A1 (en) 2022-05-26
MX2022012353A (es) 2022-10-31
KR102732030B1 (ko) 2024-11-20
AU2021248212A1 (en) 2022-12-01
CA3212191A1 (en) 2021-10-07
CN115379842A (zh) 2022-11-22
EP4467194A2 (en) 2024-11-27
CA3163321A1 (en) 2021-10-07
WO2021201239A1 (en) 2021-10-07
TW202200142A (zh) 2022-01-01
ZA202210633B (en) 2025-01-29
US20240374506A1 (en) 2024-11-14
EP4125903B1 (en) 2024-10-09
KR20220161403A (ko) 2022-12-06
HRP20241574T1 (hr) 2025-01-31
CN115397420A (zh) 2022-11-25
US20230129919A1 (en) 2023-04-27
TWI865760B (zh) 2024-12-11
KR20220161402A (ko) 2022-12-06
US20260115131A1 (en) 2026-04-30
JP2023520004A (ja) 2023-05-15
EP4125903C0 (en) 2024-10-09
JP2023519425A (ja) 2023-05-10
TW202200141A (zh) 2022-01-01
JP2025176037A (ja) 2025-12-03
US20260034053A1 (en) 2026-02-05
TWI906279B (zh) 2025-12-01
EP4125903A1 (en) 2023-02-08
PL4125903T3 (pl) 2025-02-03
BR112022018721A2 (pt) 2022-11-01
AU2021245713A1 (en) 2022-12-01
HUE069157T2 (hu) 2025-02-28
US20230225962A1 (en) 2023-07-20
WO2021201238A1 (en) 2021-10-07
ES2995466T3 (en) 2025-02-10
CA3136727A1 (en) 2021-10-07
MX2022012354A (es) 2022-10-31
CN119792290A (zh) 2025-04-11
BR112022018647A2 (pt) 2022-11-08

Similar Documents

Publication Publication Date Title
CA3163321C (en) Methods for dose initiation of aripiprazole treatments
EP2767285B2 (en) TABLET COMPRISING 7-[4-(4-BENZO[b]THIOPHEN-4-YL-PIPERAZIN-1-YL) BUTOXY]-1H-QUINOLIN-2-ONE OR A SALT THEREOF
JP6309454B2 (ja) 癌の併用処置
US20230241087A1 (en) Methods Of Treating Cancer Using Prmt5 Inhibitors
KR20140129164A (ko) 히스톤 데아세틸라아제 억제제 및 파조파닙의 조합물 및 이의 용도
EP2059245A1 (en) Bifeprunox doses for treating schizophrenia
JP2025509278A (ja) 小細胞肺癌を治療する方法
CN105616411A (zh) 治疗结肠癌的组合物及其应用
US20150209337A1 (en) Nicotinamide derivate in the treatment of acute coronary syndrome
HK40120297A (en) Methods for dose initiation of aripiprazole treatments
HK40081123A (en) Methods for dose initiation of aripiprazole treatments
US20240165082A1 (en) Orally administered compositions for cancer treatment
CN102083436A (zh) 抗肿瘤组合物和方法
CN101573117A (zh) 用于治疗精神分裂症的联苯芦诺剂量
TWI334349B (en) Pain threshold reduction depressant
Chow et al. PII‐54: CYP3A5 but not CYP2D6 polymorphism affects dextropropoxyphene disposition in human subjects
HK1195740B (en) TABLET COMPRISING 7-[4-(4-BENZO[b]THIOPHEN-4-YL-PIPERAZIN-1-YL)BUTOXY]-1H-QUINOLIN-2-ONE OR A SALT THEREOF

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230130

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250304

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250304

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250304

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260303

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260303